Infectious Disease Frontier

With continuous advancements in technology and deepening research in the field of AIDS prevention, new breakthroughs in HIV treatment and management have emerged. During the 25th International AIDS Conference, "Infectious Diseases Frontier" invited Dr. Hui Wang from Shenzhen Third People's Hospital and Dr. Huachun Zou from the Fudan University School of Public Health for an in-depth dialogue. They shared the latest research findings on the impact of integrase inhibitors (INSTIs) on patients' weight and BMI and discussed the challenges faced in HIV treatment and management. Furthermore, significant progress has been made in HIV prevention, with the clinical trial of Gilead's PrEP drug Lenacapavir—administered once every six months—showing remarkable results among South African women. This series of research findings not only advances the development of AIDS treatment but also provides new insights and directions for global AIDS prevention strategies.

Recently, the 20th Shanghai International Forum for Infection Control (SIFIC) and the 8th Oriental Forum on Complex Infectious Diseases (OFCID), along with the Annual Academic Meeting of the Global Chinese Clinical Microbiology and Infectious Diseases Society, were successfully held in Shanghai. Infectious Diseases Frontier had the privilege of interviewing several administrators of the SIFIC forum at the event. They shared the development journey of SIFIC and their personal growth stories from different perspectives. Through these real experiences, we gained insight into how SIFIC, with an open attitude and innovative spirit, is leading the development of infection control in China, while also witnessing how each participant has achieved personal growth and value enhancement in this process.

On July 24th, during the highly anticipated Co-Chairs' Choice session at the 25th International AIDS Conference in Munich, Germany, the PURPOSE 1 study was unveiled, highlighting a significant breakthrough in HIV prevention. The study demonstrated the exceptional efficacy of the long-acting injectable drug Lenacapavir in preventing HIV infection among women. The study was simultaneously published online in The New England Journal of Medicine. Conducted in South Africa and Uganda, this double-blind, randomized controlled trial compared different prevention strategies and found that biannual injections of Lenacapavir effectively blocked HIV infection, resulting in zero cases of infection. The efficacy of Lenacapavir far surpassed that of daily oral F/TAF and F/TDF. The study not only confirmed Lenacapavir's high effectiveness but also revealed its potential to improve patient adherence, offering a new solution to one of the major challenges in HIV prevention. With the widespread application of Lenacapavir, global HIV prevention strategies may be poised for significant change. Infectious Diseases Frontier invited Dr. Hui Wang from the Second Affiliated Hospital of Southern University of Science and Technology (Shenzhen Third People's Hospital) to provide an in-depth commentary and analysis of this study.

The 20th Shanghai International Forum for Infection Control (SIFIC) and the 8th Oriental Forum on Complex Infectious Diseases (OFCID), jointly held with the Global Chinese Society of Clinical Microbiology and Infectious Diseases (GCSCMID) Annual Meeting, successfully took place at the Shanghai International Convention Center from July 25-27, 2024. During the event, Dr. Fan Wu from Medical School of columbia University  delivered in-depth presentations on "Individual Diagnosis and Treatment of Candida auris Infections and Population-Level Prevention and Control" and "Mother-to-Child Transmission of Babesiosis - A Potentially Dangerous Blood Parasitic Disease." In an interview with "Infectious Diseases Frontier," Dr. Wu further elaborated on the global threat posed by Candida auris and the challenges in controlling Babesiosis, providing new insights and directions for the field of infection control.